Skip to content

Pfizer’s Omicron-Fighting Shots Spur Strong Immune Response

  • Study tested two vaccine candidates with partner BioNTech
  • FDA advisers to meet next week on changes to fight variants
Prepared doses of the Pfizer-BioNTech Covid-19 vaccine.

Prepared doses of the Pfizer-BioNTech Covid-19 vaccine.

Photographer: Andre Malerba/Bloomberg
Updated on

Pfizer Inc.’s experimental omicron-targeting vaccines prompted strong immune responses in a study that may pave the way for the use of next-generation Covid-19 shots better tailored to fight new variants. 

Pfizer and its partner, Germany-based BioNTech SE, said a booster dose of a vaccine designed to target omicron, as well as a hybrid shot that that fights the original strain and omicron, both elicited a “substantially higher” immune response against omicron subvariant BA.1 when compared with their existing Covid-19 vaccine.